AAV Gene Therapy Process
Development & CMC Consulting

Phase-appropriate viral vector manufacturing development that accelerates your AAV gene
therapy program, from construct design through commercial scale-up and BLA filing.

Efficient & Results-Driven Driving Success Across the Drug Development Lifecycle

Your product is your manufacturing and testing process. By building robust processes and analytics early in the drug product lifecycle, DES Pharma ensures you get your AAV gene therapy, and all biologics, to patients safely and efficiently.

Using our extensive experience in AAV gene therapy manufacturing, viral vector process development, and CMC regulatory strategy, we eliminate wasted effort and experimentation, delivering fast, reliable, and compliant drug supply to meet your clinical and corporate milestones.

🧬

AAV Gene Therapy Manufacturing Services

Specialized capabilities for adeno-associated virus development across all platforms and serotypes

Including AAV capsid development, producer cell line optimization, and viral vector manufacturing scale-up. Our consultants have hands-on experience with AAV2, AAV5, AAV8, AAV9, and novel capsid variants across triple plasmid transfection, baculovirus insect cell, and HSV helper virus platforms.

🚀Capsid Optimization & Selection
🚀Producer Cell Line Development
🚀Baculovirus Platform Transfer
🚀Empty/Full Capsid Ratio Control
🚀Suspension Scale-Up (adherent → suspension)
🚀Downstream Purification Strategy
🚀Transient Transfection Optimization
🚀Viral Clearance Study Design

A Phase-Appropriate CMC Approach Cutting Out Excess &
Risks at Every Stage

Fast-tracking drug development and optimizing patient safety, production efficiency, and supply reliability to accelerate market access for AAV gene therapies and biologics.

Begin with the Commercial End State in Mind

Construct design through toxicology lot production, IND authorship & AAV platform selection

Lay the Groundwork for Reliable Clinical Supply

Tech transfer, scale-up, CDMO selection & IND amendment support

Ensure Process Control & Submission Readiness

PPQ, BLA filing, process characterization & viral clearance studies
 

Maintain Compliance & Expand Your Market

Continuous process validation, lifecycle management & site tech transfer

AAV Manufacturing Expertise Specialized Viral Vector Process Development

At DES Pharma, we bring deep expertise in AAV gene therapy manufacturing across all serotypes and production platforms. Our consultants have hands-on experience with AAV2, AAV5, AAV8, AAV9, and novel capsid variants, supporting programs through every critical development milestone from construct design through commercial manufacturing.

We understand the unique challenges of viral vector process development: optimizing empty/full capsid ratios, scaling from adherent to suspension cell culture, selecting appropriate downstream purification strategies, and navigating complex regulatory expectations for gene therapy CMC.

Whether transitioning from triple plasmid transfection to a baculovirus insect cell system, preparing your first IND submission, or executing PPQ batches ahead of a BLA, our team delivers the technical depth and regulatory insight to accelerate your program and meet FDA and EMA expectations.

Triple Plasmid → Baculovirus Platform Transitions

Comparative platform assessment, technology transfer packages, and manufacturing robustness evaluation for HEK293 and Sf9 cell-based systems

Upstream Bioreactor Scale-Up

Adherent to suspension adaptation, bioreactor optimization (wave, stirred-tank), MOI and infection timing studies, and cell viability management

Downstream Purification Strategy

Ultracentrifugation, iodixanol gradient, affinity chromatography (AAVX, AVB Sepharose), and ion-exchange polishing (platform and custom approaches)

Empty/Full Capsid Control & Optimization

Analytical ultracentrifugation (AUC), AEX chromatography strategies, and process modification to achieve target full capsid percentage specifications

IND CMC Module 3.2 Authorship

Gene therapy-specific manufacturing section drafting, process description, critical quality attributes, and FDA/EMA-aligned regulatory strategy

Rational Design, Reliable Results Emphasizing Process
Design & Product Quality

Our core principles drive measurable outcomes for AAV gene therapy
and biologics programs at every stage.

High Product Quality

Built on rational, data-driven process design that establishes critical quality attributes (CQAs) and process parameters from day one.

Timeline Acceleration

We perform only the core experiments necessary to achieve meaningful results, eliminating non-essential studies that delay IND and BLA timelines.

Supply Reliability

Our process helps ensure robust supply and predictable manufacturing performance, critical for gene therapy programs with complex logistics requirements.

Proven Technologies

We leverage established manufacturing platforms and validated analytical methods to minimize technical risk and regulatory uncertainty.

Regulatory Alignment

Deep knowledge of FDA and EMA gene therapy CMC expectations, ICH Q8/Q9/Q10/Q11, and current CBER guidance for viral vectors.

CDMO Partnership Support

End-to-end CDMO selection, RFP management, technical due diligence, and tech transfer oversight for AAV and biologics manufacturing.

Supply Planning & Commercial Readiness Strategic Planning for Reliable Supply

With experience in commercial processes, DES Pharma guides program development toward outcomes that meet both patient and corporate needs efficiently, including the unique supply chain requirements of viral vector gene therapy products.

Supply Modeling Driving Scalable Success

Demand planning, capacity allocation, and yield modeling to ensure you never face clinical material shortfalls.

Vendor Selection & Facility Design

Comprehensive CDMO assessment including facility capabilities, GMP compliance status, and capacity commitments for AAV manufacturing.

Sufficient Clinical & Commercial Material

Scale-up strategy ensuring manufacturing capacity meets clinical enrollment projections and eventual commercial demand.

Get Started Advance Your AAV Gene Therapy Program with Confidence

Start building a reliable, regulatory-ready viral vector manufacturing process today.